WEBINARS/EVENTS

• Getting Ready For SUT X-Ray Irradiation

  In this webinar we compare gamma and X-ray irradiation and explain what testing has been completed and key milestones for readiness for industry.

• How To Scale Up The Production Of Therapeutic Viral Vectors For Gene Therapy Applications

  Learn how you can develop reproducible and scalable processes for viral vector manufacturing in order to meet clinical and commercial market demand in very short timelines.

• Pathways To Success: Expert Insights On Single-Use Technology

  Explore collaboration between biomanufacturers and suppliers, and how partnerships can speed up single-use process implementation and reduce risk.

• How Filter Plates Can Streamline Your Workflow

  In this webinar you will learn how to choose the best filter plate for your specific applications and understand pore size, membrane material, well volumes and tip types.

• Knowledge Transfer, Training Collaboration For Suppliers & Manufacturers

  A case study in how Pall Corporation and Lonza successfully worked together to create an effective training program.

• Biotech Integrated Solutions From Process Engineering Project Management Experts

  Scaling gene therapy, mAb, or vaccine therapeutic drug products from bench to manufacturing involves a balancing act between project management, risk mitigation, and process parameter selection. In this webinar we explore the ways to apply best practices through implementation of the Biotech Integrated Solutions service architecture for large-scale manufacturing projects, ultimately accelerating speed to market.

• Gene Therapy Downstream Manufacturing, Scale-up And Best Practices

  Join our panel webinar and meet the authors of the recently published gene therapy Ebook: ‘Insights on Successful Gene Therapy Manufacturing and Commercialization’ downstream article.  Hear directly from the authors on various topics related to gene therapy manufacturing and commercialization, the current state of the industry and how we can continue to advance these life-changing medicines.

• Gene Therapy Upstream Manufacturing, Scale-up And Best Practices

  Gene therapies provide innovative options for treating patients, particularly where other traditional therapeutics have been ineffective. The industry continues to grow and mature from research to approved therapeutics. In this panel webinar series, hear directly from the authors of the eBook  "Insights on Successful Gene Therapy Manufacturing and Commercialization" on various topics related to gene therapy manufacturing and commercialization, the current state of the industry and how we can continue to advance these life-changing medicines.

• Freezing Biologics For Storage And Transport

  The process of freezing biologics for storage and transport is expected to play an increasingly important role in optimizing the supply chain as markets and production sites become more diverse. As the chosen freezing method can affect both product quality and amount of product loss, it is important to fully understand this critical step in the process. In this video we discuss an end-to-end solution to fill, freeze, transport and thaw bulk drug substances.

• Implementing Single-Use Technologies In Formulation And Filling Of Vaccines

  Formulation and filling is a critical part of any drug manufacturing process and demands the highest levels of quality and reliability. Pall has a range of technologies and services that enables end users to carry out their operations with increased reliability and flexibility – while ensuring the product quality is designed into the manufacturing process. Using technology from the Allegro™ single-use portfolio, Pall sterilizing grade filters and Pall’s automated solutions ensure that manual interventions are minimized and increased sterility assurance is achieved.

• Downstream Process Development For Vaccine Manufacturing

  The purification of vaccines and gene therapy/viral vector products is a key part of a drug manufacturing process that requires high levels of product purity and process reproducibility. Pall has a range of technologies and offers field-based support and lab-based process development services that enable end users to purify and recover their high-value products. The process strategies to improve purity and yield as well as the challenges associated the purification of viral vector process will be discussed.

• Developing Scalable Upstream Workflows For Recombinant And Viral Vaccine Processes

  Vaccine manufacturing is responding to challenges for increasing safety assurance and responsiveness in order to reduce the impact of pandemic such as SARS-CoV-2. Therefore, in-depth knowledge of microorganism pathogenicity leads to develop new type of vaccines such as recombinant and viral vaccines. In this presentation we will review the current main upstream vaccine production processes, considering the choice of expression system, the means by which the biological preparation is introduced into the production cell and how Pall’s flexible single-use bioreactors support rapid process development, scale-up and safeguard the quality of life-protecting vaccines and help assure compliance with cGMP.

• Vaccines Development, Regulations And Manufacturing Part-2

  In Part 2, we will review vaccine processes with examples based upon influenza vaccine, inactivated Polio vaccine and an overview of the different types of vaccine production processes from cell expansion, USP and DSP, to the formulation and filling operations to make the finished product. We will talk about vaccine production facilities, how equipment is integrated their operating principles and biological safety levels for containment. Finally, we will look at the vaccine industry today, the supply chain and globalization, and how important vaccines are in pandemic preparedness, availability, and time to market.

• Vaccines Development, Regulations And Manufacturing Part-1

  This two-part webinar will focus on vaccines and an overview of their science, technology and, manufacturing processes. In Part 1, we will focus on the timelines and organizations involved, regulatory, quality and safety testing, and the different components and activities that contribute to their development including, antigens and adjuvants. The strategies and different philosophies which facilitate process optimization and scale-up, such as QbD and how the cost of a vaccine is assessed will also be studied.